Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck-Teva Legal Wrangle Over Januvia "R&D" In India

Executive Summary

Merck & Co continues to keep a hawk eye on alleged infringement activities in India pertaining to its diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride). It has hauled Teva to court for allegedly manufacturing and selling sitagliptin, though the Israeli multinational has claimed that its efforts were geared only towards regulatory submissions.

You may also be interested in...



Legal Wrangles: Foreign Firms Gaming The System In India?

Indian companies have cried foul over what they claim are "unethical" practices deployed by foreign firms in the legal arena, among others, to safeguard their "patent monopoly".

Merck Wards Off More Januvia Infringers In India

Merck & Co has moved to fend off a clutch of smaller Indian players that allegedly contract manufacture and export its diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride), or hope to introduce copies of these on the domestic market, infringing on its patents.

Permanent Bar Against Glenmark's Sitagliptin Copies

The Delhi High Court has permanently enjoined Glenmark Pharmaceuticals Ltd from making and selling its generic version of Merck & Co's diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride). The Indian firm has been found to have infringed the sitagliptin patent.

Topics

Related Companies

UsernamePublicRestriction

Register

SC065490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel